IL262720B2 - טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי - Google Patents

טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי

Info

Publication number
IL262720B2
IL262720B2 IL262720A IL26272018A IL262720B2 IL 262720 B2 IL262720 B2 IL 262720B2 IL 262720 A IL262720 A IL 262720A IL 26272018 A IL26272018 A IL 26272018A IL 262720 B2 IL262720 B2 IL 262720B2
Authority
IL
Israel
Prior art keywords
treprostinil
dose
micrograms
dry powder
particles
Prior art date
Application number
IL262720A
Other languages
English (en)
Other versions
IL262720A (he
IL262720B1 (he
Original Assignee
Liquidia Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL262720(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liquidia Tech Inc filed Critical Liquidia Tech Inc
Publication of IL262720A publication Critical patent/IL262720A/he
Publication of IL262720B1 publication Critical patent/IL262720B1/he
Publication of IL262720B2 publication Critical patent/IL262720B2/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL262720A 2016-05-05 2017-05-05 טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי IL262720B2 (he)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662332013P 2016-05-05 2016-05-05
US201662404960P 2016-10-06 2016-10-06
US201662440078P 2016-12-29 2016-12-29
US201762472204P 2017-03-16 2017-03-16
PCT/US2017/031301 WO2017192993A1 (en) 2016-05-05 2017-05-05 Dry powder treprostinil for the treatment of pulmonary hypertension

Publications (3)

Publication Number Publication Date
IL262720A IL262720A (he) 2018-12-31
IL262720B1 IL262720B1 (he) 2024-02-01
IL262720B2 true IL262720B2 (he) 2024-06-01

Family

ID=60203775

Family Applications (3)

Application Number Title Priority Date Filing Date
IL262720A IL262720B2 (he) 2016-05-05 2017-05-05 טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי
IL310250A IL310250B2 (he) 2016-05-05 2017-05-05 טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי
IL319790A IL319790A (he) 2016-05-05 2017-05-05 טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL310250A IL310250B2 (he) 2016-05-05 2017-05-05 טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי
IL319790A IL319790A (he) 2016-05-05 2017-05-05 טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי

Country Status (7)

Country Link
US (7) US10898494B2 (he)
EP (1) EP3452170A4 (he)
JP (3) JP2019519489A (he)
AU (3) AU2017261317A1 (he)
CA (1) CA3023257A1 (he)
IL (3) IL262720B2 (he)
WO (1) WO2017192993A1 (he)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
CA2876297C (en) * 2012-06-15 2019-02-26 Case Western Reserve University Therapy delivery devices and methods for non-damaging neural tissue conduction block
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
ES2860975T3 (es) 2013-10-25 2021-10-05 Insmed Inc Compuestos de prostaciclina
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US20190321290A1 (en) * 2016-01-29 2019-10-24 Mannkind Corporation Composition and method for inhalation
IL262720B2 (he) 2016-05-05 2024-06-01 Liquidia Tech Inc טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי
CA3102967A1 (en) * 2018-06-07 2019-12-12 Mannkind Corporation Composition and method for inhalation
CN114072136B (zh) * 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
US20210022994A1 (en) 2019-07-22 2021-01-28 Lupin Holdings, B.V. Sustained release trepostinil-compound microparticle compositions
JP2023523557A (ja) 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル
WO2022094100A1 (en) * 2020-10-28 2022-05-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
KR20240093906A (ko) * 2021-10-27 2024-06-24 맨카인드 코포레이션 폐고혈압을 치료하기 위한 방법 및 조성물
WO2023154705A1 (en) * 2022-02-08 2023-08-17 United Therapeutics Corporation Treprostinil iloprost combination therapy
EP4516297A4 (en) * 2022-04-29 2026-02-25 Zhaoke pharmaceutical guangzhou co ltd Treprostinil Gentle Inhalation Mist
WO2025174856A1 (en) * 2024-02-12 2025-08-21 Mannkind Corporation Process for making a composition for pulmonary inhalation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161234A2 (en) * 1999-03-18 2001-12-12 United Therapeutics Corporation Method for delivering benzidine prostaglandins by inhalation
US20080200449A1 (en) * 2006-05-15 2008-08-21 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
WO2016057712A1 (en) * 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56122328A (en) 1980-02-29 1981-09-25 Sumitomo Chem Co Ltd Crystalline amine salt of methanoplastocyclin, its preparation and purifying method
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
US5441060A (en) 1993-02-08 1995-08-15 Duke University Dry powder delivery system
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US20030118567A1 (en) 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US7305986B1 (en) * 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US6242482B1 (en) 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
ES2622471T5 (es) 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
US7954491B2 (en) 2003-06-13 2011-06-07 Civitas Therapeutics, Inc. Low dose pharmaceutical powders for inhalations
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
EP1694731B1 (en) 2003-09-23 2012-03-28 University Of North Carolina At Chapel Hill Photocurable perfluoropolyethers for use as novel materials in microfluidic devices
DE602004028155D1 (de) 2003-12-16 2010-08-26 United Therapeutics Corp Verwendung von treprostinil zur behandlung von ischämischen läsionen
ATE441418T1 (de) 2003-12-16 2009-09-15 United Therapeutics Corp Verwendung von treprostinil zur verbesserung der nierenfunktion
MXPA06006738A (es) 2003-12-19 2006-08-31 Univ North Carolina Metodos para fabricar micro- y nano-estructuras aisladas utilizando litografia suave o de impresion.
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
WO2005099680A2 (en) 2004-04-12 2005-10-27 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
JP2008507585A (ja) 2004-07-26 2008-03-13 コセリックス インク 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
EP2537657A3 (en) 2005-08-09 2016-05-04 The University of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
WO2007133808A2 (en) 2006-05-15 2007-11-22 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
CN101505821A (zh) * 2006-06-16 2009-08-12 希普拉有限公司 改进的干燥粉末吸入器
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
EP2207670B1 (en) 2007-10-12 2019-05-22 Liquidia Technologies, Inc. Method for producing particles and patterned films
CN101903324B (zh) 2007-12-17 2013-07-03 联合治疗公司 一种制备Remodulin中的活性成分曲前列素的改良方法
EP2262480B1 (en) 2008-03-04 2018-02-14 Liquidia Technologies, Inc. Immunomodulator particles
WO2009117112A2 (en) * 2008-03-21 2009-09-24 Novartis Ag Powder dispersion apparatus, method of making and using the apparatus, components that can be used on the apparatus and other devices, and various active agents
CA2723540C (en) 2008-05-08 2016-01-05 United Therapeutics Corporation Treprostinil monohydrate
EP2299990A1 (de) 2008-06-09 2011-03-30 Boehringer Ingelheim International GmbH Neue einbettungspartikel für die inhalation
WO2009152160A1 (en) * 2008-06-10 2009-12-17 Gilead Sciences, Inc. Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension
CN102164487A (zh) 2008-09-25 2011-08-24 阿拉迪姆公司 曲前列素的深肺部递送
KR101690643B1 (ko) 2008-12-05 2016-12-28 리퀴디아 테크놀로지스 인코포레이티드 패턴 재료 제조 방법
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
JP5656996B2 (ja) 2009-07-13 2015-01-21 ザ ユニバーシティ オブ ノース キャロライナ アット チャペル ヒル 工学的に作製されたエアロゾル粒子、およびそれに関連した方法
RS53234B (sr) 2009-08-07 2014-08-29 Scipharm Sàrl Kompozicija za lečenje cistične fibroze
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
EP2538969A4 (en) 2010-02-22 2013-11-27 Liquidia Technologies Inc VACCINES FROM POLYSACCHARIDE PARTICLES
CA2726599C (en) 2010-12-30 2017-07-25 Alphora Research Inc. Process for treprostinil salt preparation
US10213464B2 (en) 2011-01-13 2019-02-26 Scipharm Sarl Method for enhancing engraftment of haematopoetic stem cells
JP5780775B2 (ja) 2011-02-18 2015-09-16 株式会社Ｌｔｔバイオファーマ プロスタグランジンｉ２誘導体を含有するナノ粒子
EP2526926A1 (de) 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation
HK1198358A1 (en) 2011-08-12 2015-04-10 Ascendis Pharma A/S Sustained release composition of prostacyclin
ES2769270T3 (es) 2011-09-30 2020-06-25 Bluebird Bio Inc Compuestos para transducción viral mejorada
CN108771655A (zh) * 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
NZ629438A (en) 2012-02-28 2016-10-28 Iceutica Holdings Inc Inhalable pharmaceutical compositions
CN107596518B (zh) * 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
ES2672239T3 (es) 2012-03-15 2018-06-13 Steadymed Ltd. Reducción mejorada del dolor en el lugar de infusión para dispositivos de administración de fármacos
EP2879682B1 (en) 2012-08-01 2018-03-21 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
AU2013351934B2 (en) * 2012-11-30 2018-03-29 Insmed Incorporated Prostacylin compositions and methods for using the same
US9505737B2 (en) * 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP2971228B1 (en) 2013-03-11 2023-06-21 Si02 Medical Products, Inc. Coated packaging
JP2016517410A (ja) 2013-03-14 2016-06-16 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの固体形態
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
US9758465B2 (en) 2013-04-30 2017-09-12 United Therapeutics Corporation Controlled release pharmaceutical formulations
US9349730B2 (en) 2013-07-18 2016-05-24 Globalfoundries Inc. Fin transformation process and isolation structures facilitating different Fin isolation schemes
US9925184B2 (en) * 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
ES2860975T3 (es) * 2013-10-25 2021-10-05 Insmed Inc Compuestos de prostaciclina
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
KR20160117596A (ko) 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
WO2015138423A1 (en) * 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
CA3012679C (en) 2016-01-29 2023-12-12 Mannkind Corporation Dry powder inhaler
US20190321290A1 (en) 2016-01-29 2019-10-24 Mannkind Corporation Composition and method for inhalation
IL262720B2 (he) 2016-05-05 2024-06-01 Liquidia Tech Inc טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי
MX2019006938A (es) 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
CA3102967A1 (en) 2018-06-07 2019-12-12 Mannkind Corporation Composition and method for inhalation
ES2976468T3 (es) 2018-09-18 2024-08-01 Lilly Co Eli Sal de treprostinil erbumina
CN112313202A (zh) 2019-05-21 2021-02-02 江苏众强药业有限公司 曲前列尼尔钠盐新晶型及制备方法
US20210022994A1 (en) 2019-07-22 2021-01-28 Lupin Holdings, B.V. Sustained release trepostinil-compound microparticle compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161234A2 (en) * 1999-03-18 2001-12-12 United Therapeutics Corporation Method for delivering benzidine prostaglandins by inhalation
US20080200449A1 (en) * 2006-05-15 2008-08-21 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
WO2016057712A1 (en) * 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension

Also Published As

Publication number Publication date
US11744835B2 (en) 2023-09-05
US20210353641A1 (en) 2021-11-18
US11712442B2 (en) 2023-08-01
JP2025118785A (ja) 2025-08-13
US10898494B2 (en) 2021-01-26
US12390475B2 (en) 2025-08-19
US20210077504A1 (en) 2021-03-18
IL319790A (he) 2025-05-01
EP3452170A4 (en) 2020-04-01
US20230346799A1 (en) 2023-11-02
IL262720A (he) 2018-12-31
US20220257608A1 (en) 2022-08-18
IL310250A (he) 2024-03-01
AU2025204321A1 (en) 2025-06-26
US20210353640A1 (en) 2021-11-18
JP2023071844A (ja) 2023-05-23
IL262720B1 (he) 2024-02-01
IL310250B2 (he) 2025-09-01
CA3023257A1 (en) 2017-11-09
US11744836B2 (en) 2023-09-05
WO2017192993A1 (en) 2017-11-09
US20190151332A1 (en) 2019-05-23
JP2019519489A (ja) 2019-07-11
US11660304B2 (en) 2023-05-30
IL310250B1 (he) 2025-05-01
US20250332175A1 (en) 2025-10-30
EP3452170A1 (en) 2019-03-13
AU2017261317A1 (en) 2018-12-13
AU2023201307A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
IL262720B2 (he) טרפוסטיניל בצורת אבקה יבשה לטיפול ביתר לחץ דם ריאתי
JP7391039B2 (ja) 肺疾患の処置に使用するための吸入可能なリポソーム徐放性組成物
RU2275900C2 (ru) Способ высокоэффективной доставки аэрозоля с большой терапевтической массой
TWI539979B (zh) 用於經由肺部遞送長效蕈毒鹼拮抗劑及長效β腎上腺素受體激動劑之組成物，及相關方法及系統
HK1254627A1 (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20240122889A1 (en) Dry powder compositions of treprostinil prodrugs and methods of use thereof
IL302994A (he) אימטיניב נשאף עבור שדה יתר לחץ דם ריאתי
AU2015201037B2 (en) Respiratory delivery of active agents
IL323261A (he) פורמולציה של טרפרוסטיניל המיובשת בריסוס
WO2023119093A1 (en) Compositions, methods and systems for aerosol drug delivery
AU2016202397B2 (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
JP6915956B2 (ja) 肺線維症の１日１回の治療
AU2017201626A1 (en) Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems